Asset profile
Pilavapadin
Small molecule
Evidence outlook · lead readout
PROGRESS (NCT06203002) · Diabetic Peripheral Neuropathic Pain
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
PROGRESS (NCT06203002): The study randomized 496 participants to blinded pilavapadin regimens or matching placebo, with participants, care providers, investigators, and outcome assessors masked. Its primary clinical endpoint was change in average daily pain score at Week 8. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
15 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 15 same-indication; 9 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pilavapadin: this drug | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Suzetrigine | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | ||
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| HL-1186 | Phase 2/3 | Small molecule | — | ||
| HRS-2129 | Phase 2/3 | Small molecule | — | ||
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | ||
| NRD135S.E1 | Phase 2 | Small molecule | — | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| AJH-2947 | Phase 1 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.